 | • レポートコード：C-MOR-100128 • 出版社/出版日：Mordor Intelligence / 2019年9月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site License | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、生物学的安全性試験の世界市場について調査・分析し、生物学的安全性試験の世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。 |
Market Overview
Global Biological Safety Testing Market is expected to witness a CAGR of 12.4% during the forecast period. Certain factors that are driving the market growth include growth in pharmaceutical and biotechnology industries along with increasing investments and increasing production of new biologics due to high disease burden.
The biotechnology-derived products or biologicals have effectively made their way into various aspects of healthcare including diagnosis, prevention as well as treatment of disease. However, there remain potential safety concerns which generally arise from their manufacturing processes and also from the complex biological and structural characteristics of these products. Therefore, such products require detailed and systematic biological safety testing which eventually enables for adequate assessment of safety before any kind of clinical investigation. Hence, the market is expected to observe significant growth all across the globe over the forecast period.
Scope of the Report
Biological safety testing refers to the testing procedures which are carried out to ensure non-contamination of biopharmaceuticals and vaccines and also in order to comply with regulations regarding the same. These include various types of sterility tests, cell line authentication, and characterization tests, bioburden tests, endotoxin tests, adventitious agent detection tests, residual host contamination detection tests, etc.
Key Market Trends
Vaccines and Therapeutics is Expected to Hold Significant Market Share in the Application Segment
Vaccination is considered the most effective way of preventing infection and severe outcomes caused by a number of deadly viruses. Every licensed and recommended vaccine has to go through years of safety testing including testing and evaluation of the vaccine before it’s licensed by the Food and Drug Administration (FDA) and recommended for use by the Centers for Disease Control and Prevention (CDC). The safety testing also includes the monitoring of the vaccine’s safety after it is recommended for infants, children, or adults. Once a vaccine gets approval, it continues to be tested. The company that manufactures the vaccine continues to test batches to make sure the vaccine is potent, pure, and sterile.
North America Dominates the Market and Expected to do Same in the Forecasted Period
The growth of the biological safety testing market in North America can be directly attributed to the growing biotechnology and pharmaceutical industry in the region. The high growth of these industries is further attributable to factors such as innovative technologies and the presence of favorable government initiatives. Furthermore, advanced healthcare infrastructure and rising R&D spending should further spur revenue size.
Competitive Landscape
The global Biological Safety Testing market is highly competitive and consists of a few major players. Companies like Avance Biosciences, Cytovance Biologics, Eurofins Scientific, Lonza, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Toxikon, WuXi AppTec, among others, hold the substantial market share in the Biological Safety Testing market.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in Pharmaceutical and Biotechnology Industries along with Increasing Investments
4.2.2 Increasing Production of New Biologics due to High Disease Burden
4.3 Market Restraints
4.3.1 Time Consuming Approval Process
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product
5.1.1 Reagents & Kits
5.1.2 Instruments
5.1.3 Others
5.2 Application
5.2.1 Vaccines & Therapeutics
5.2.2 Cellular and Gene Therapy
5.2.3 Blood & Blood-based Therapy
5.2.4 Others
5.3 Test
5.3.1 Sterility tests
5.3.2 Cell Line Authentication and Characterisation Tests
5.3.3 Bioburden tests
5.3.4 Endotoxin tests
5.3.5 Adventitious Agent Detection Tests
5.3.6 Others
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Avance Biosciences
6.1.2 Cytovance Biologics
6.1.3 Eurofins Scientific
6.1.4 Lonza
6.1.5 Merck KGaA
6.1.6 Promega Corporation
6.1.7 Thermo Fisher Scientific
6.1.8 Toxikon
6.1.9 WuXi AppTec
7 MARKET OPPORTUNITIES AND FUTURE TRENDS